Name

Carterra- LSA platform

Legal name

Carterra, Inc.

Website

https://carterra-bio.com/lsa

Company type

Private

Founded year

2018

Operating status

Operating

Ownership category

akta.pro rank

Product category

Biopharmaceutical Analytical Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

SIC

Laboratory Analytical Instruments (3826)

akta.pro primary industry

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Surface plasmon resonance
• Antibody screening platforms
• Kinetics characterization
• Epitope binning systems
• Biopharmaceutical instrumentation

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. SPR Instrumentation Sales: Sale of high-throughput SPR instruments including LSA, LSAXT, Ultra, and Carterra Vega platforms. Instruments are capital equipment requiring significant investment, sold through enterprise field sales.
2. Sensor Chips and Consumables: Recurring revenue from proprietary sensor chips (HC, CMD, NiNTA, Streptavidin, Protein A/G series) and consumables required for SPR operations. Online store available for chip purchases.
3. Software Licenses and Updates: Kinetics and Epitope Data Analysis Software with regular version updates. Software updates released periodically (e.g., V.2.0.0.5078 in October 2025) with new features and capabilities.
4. Service and Support: Technical support, application training programs, and service contracts for installed customer base. Dedicated support team with phone and email contact options.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Carterra designs, manufactures, and sells high-throughput Surface Plasmon Resonance (HT-SPR) instrumentation and associated consumables and software for antibody screening, kinetic characterization, and epitope binning. The LSA, LSAXT, Ultra, and Vega instruments measure binding interactions for therapeutic discovery at biopharmaceutical companies, biotechs, and academic and government research organizations, complemented by proprietary sensor chips, Navigator control software, and Kinetics and Epitope Data Analysis Software.

Product overview

Carterra offers a portfolio of four HT-SPR (High-Throughput Surface Plasmon Resonance) platforms sharing common technology and software. The Carterra LSA serves as the core antibody characterization platform for detailed kinetics and epitope binning. The LSAXT extends capabilities with enhanced sensitivity for PROTACs, kinases, and cytokines. The Ultra platform targets small molecule and fragment screening with maximum sensitivity. The Vega represents the latest addition as a 48-channel parallel SPR platform for massively increased throughput. All instruments share common Navigator software for experiment control, Kinetics Data Analysis Software for kinetic screening, and Epitope Data Analysis Software for binning analysis. The platforms are complemented by a range of sensor chip consumables and integrated AI/ML tools for data-driven drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

• Carterra LSA: High-throughput SPR platform for detailed antibody kinetic and epitope binning characterization, supporting up to 384x384 interactions.
• Carterra LSAXT
• Carterra Ultra
• Carterra Vega
• Kinetics Data Analysis Software
• Epitope Data Analysis Software

Products and services

• Carterra LSA High-throughput SPR instrument for detailed antibody kinetic analysis and epitope binning, enabling screening of up to 1,152 monoclonal antibodies in a single unattended run for pharmaceutical and biotech discovery teams.
• Carterra LSAXT Enhanced sensitivity SPR instrument for PROTAC, kinase, cytokine, DEL, and protein-protein inhibitor screening and characterization, designed for biotherapeutic discovery teams.
• Carterra Ultra High-sensitivity HT-SPR instrument for small molecule and fragment screening with 96-channel printhead, advanced microfluidics, and capacity for up to 768 fragments or 1,152 mAbs per run.
• Carterra Vega 48-channel parallel HT-SPR platform delivering 12x the throughput of leading 8-channel SPR systems, screening over 20,000 analytes per day for high-volume biotherapeutic and small molecule discovery programs.
• Sensor Chips Proprietary biosensor chips including HC, CMD, NiNTA, Streptavidin, Protein A, and Protein A/G surface chemistries used as consumables for Carterra HT-SPR instruments.
• Kinetics Data Analysis Software High-throughput kinetics analysis software for screening and ranking up to 1,152 monoclonal antibodies with rapid data fitting, visualization, quality validation, and interactive on-rate, off-rate, affinity, and iso-affinity plots.
• Epitope Data Analysis Software Epitope binning and mapping analysis software for processing massive 384x384 HT-SPR datasets with heat maps, dendrograms, network plots, and stacked plots for visualization.
• Navigator Software Experiment setup and run control software with assay wizards enabling complex assay setup in under 5 minutes, fully automated experiments, real-time binding data collection, and up to 7 days of unattended operation.
• AI, ML and Synthetic Biology Tools Integrated AI/ML workflows and synthetic biology tools leveraging Carterra HT-SPR binding data to support machine learning and generative AI applications in antibody design and drug discovery.

Quantifiable outcome

• 90 days from antibody screening initiation to human treatment (Eli Lilly COVID-19 antibody program)
• +3 more outcomes

Named customers18 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature8 records

Partnerships

Five partnerships are on record, tiered core and strategic.

• Revvity SignalscoreTechnology or IntegrationIntegration partnership with Revvity's Signals VitroVivo (formerly Signals Screening) software v2.7+ for data management. Enables single repository for organizing HT-SPR experimental data, comparison with orthogonal methods, and integration with TIBCO Spotfire analytics. Supports AI/ML workflows with curated data.
• Generate BiomedicinescoreTechnology or IntegrationGenerate Biomedicines uses Carterra LSA as integral part of their machine learning-driven protein design platform. Quote from Brett Blakeley, Senior Scientist: 'The Carterra LSA is the only instrument that can deliver high-resolution binding data at this level of throughput.' Demonstrates platform utility for AI/ML applications.
• AbscicoreTechnology or IntegrationAbsci uses Carterra LSA platform for AI in medical research, leveraging HT-SPR data for machine learning applications in drug discovery.
• Carna BiosciencesstrategicTechnology or IntegrationCollaboration with Carna Biosciences to develop kinase drug discovery solutions. Carterra uses Carna Biosciences kinases for demonstrating kinome profiling capabilities on their platforms.
• GSKstrategicTechnology or IntegrationGSK collaboration for DNA-encoded library screening and hit validation using HT-SPR technology. Carterra presented at GSK on high-throughput SPR applications in DEL screening.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Thermo Fisher Scientific: Thermo Fisher is a broad incumbent in life-science analytical instruments, offering a portfolio that includes biophysical characterization tools (e.g., MicroCal PEAQ-ITC, GCI systems) and adjacent label-free technologies. While not a direct SPR competitor, Thermo Fisher competes broadly for the same pharma instrument budgets.
• Bruker: Bruker operates a broader life-science instrumentation portfolio and has participated in SPR-related technologies through acquisitions. While not a single-product SPR competitor, Bruker is a broad incumbent in life-science analytical instruments that occasionally overlaps with Carterra's customer workflows.
• Agilent Technologies: Agilent provides a broad portfolio of analytical and life-science instruments, including biophysical characterization and screening tools that serve overlapping biopharma customers. While not a focused SPR competitor, Agilent competes at the portfolio level for instrument wallet share at major pharma accounts.

Others

• Revvity (formerly PerkinElmer Life Sciences): Revvity provides data management and analytics software (Signals VitroVivo/Screening) that integrates with Carterra LSA instruments for pharma screening workflows. It is an enabling technology partner and adjacent ecosystem participant rather than a direct SPR competitor.

Direct peers

• Reichert Technologies: Reichert (part of Ametek) manufactures SPR-based instruments (e.g., SR7500DC) for label-free interaction analysis in research and pharma settings. Reichert is a long-standing SPR competitor with a smaller installed base than Biacore but overlapping customer workflows in protein characterization.
• Sartorius (Octet - BLI): Sartorius markets the Octet platform based on bio-layer interferometry (BLI), the principal orthogonal label-free binding kinetics technology competing with SPR in antibody characterization and screening workflows at biopharma customers. Octet targets many of the same use cases (kinetics, epitope binning, quantitation) as Carterra's HT-SPR.
• Cytiva (Biacore): Cytiva (formerly GE Healthcare Life Sciences) manufactures the Biacore line of SPR instruments, the entrenched incumbent in label-free binding kinetics for biopharma R&D. Biacore is the closest direct competitor to Carterra across the same customer base, with decades of installed instruments at virtually every major pharma company.

Emerging players

• Nicoya Lifesciences: Nicoya offers OpenSPR, a benchtop localized surface plasmon resonance (LSPR) instrument targeted at academic and smaller biotech researchers. It is an emerging player competing in entry-level SPR workflows and represents a differentiated price-point alternative to Carterra's high-throughput platforms.
• Attana: Attana develops label-free biosensor instruments based on QCM (quartz crystal microbalance) technology for real-time interaction analysis. As a smaller, niche player in label-free kinetics, Attana competes with Carterra in select academic and biotech segments for binding characterization applications.
• NanoTemper Technologies (Monolith): NanoTemper's Monolith platform uses microscale thermophoresis (MST) for label-free binding affinity analysis, competing with SPR and BLI in protein-small molecule and protein-protein interaction characterization. It is an emerging player in adjacent label-free biophysics serving overlapping pharma/biotech customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/carterra

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Carterra- LSA platform